

Anti-GPNMB Antibody (Glembatumumab vedotin)

Introduction

Glembatumumab vedotin (CDX-011) is an ADC (Antibody-Drug Conjugates (ADCs)) consisting of a fully human IgG2 monoclonal antibody (CR011) directed against glycoprotein NMB (GPNMB) and conjugated to the potent tubulin-binding cytotoxic agent MMAE via a protease-sensitive vc linker. Glembatumumab vedotin has potent anticancer effects.

Product parameters

Alternative Names	glembatumumab, CR011, CR011-vcMMAE
Target Accession	Q14956
Target	GPNMB
CAS number	1182215-65-1
Molecular Weight	145.56 kDa
Host	CHO
Reactivity	Human
Conjugation	MMAE
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG2SA
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	The drug-to-antibody ratio (DAR) of the Anti-GPNMB Antibody (Glembatumumab vedotin) is 3.6.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

